(MUV2) Münchener Rück - Overview
Stock: Reinsurance, Health, Property-Casualty, Life, ERGO
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.45% |
| Yield on Cost 5y | 10.44% |
| Yield CAGR 5y | 19.52% |
| Payout Consistency | 98.9% |
| Payout Ratio | 50.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.6% |
| Relative Tail Risk | -8.25% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.13 |
| Alpha | 1.64 |
| Character TTM | |
|---|---|
| Beta | -0.071 |
| Beta Downside | 0.035 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.62% |
| CAGR/Max DD | 1.39 |
Description: MUV2 Münchener Rück January 29, 2026
Münchener Rückversicherungs-Gesellschaft AG (Munich Re) is a global insurer and reinsurer headquartered in Munich, Germany. It operates through five business segments: Life & Health Reinsurance, Property-Casualty Reinsurance, ERGO Life & Health Germany, ERGO Property-Casualty Germany, and ERGO International, offering a mix of traditional insurance products and digital-focused solutions such as the MIRA suite, REALYTIX ZERO, and parametric risk services.
In FY 2023 Munich Re reported gross written premiums of €120 billion, a net profit of €5.8 billion, and a combined ratio of 96.5 % in its Property-Casualty reinsurance arm-both metrics reflecting a modest improvement over the previous year. The firm’s return on equity stood at 9.2 %, while digital underwriting volumes grew 12 % YoY, driven by the expanding MIRA digital platform.
Key drivers for the reinsurance sector remain elevated natural-catastrophe loss activity (2023 NatCat events were up ~15 % YoY) and a prolonged low-interest-rate environment that pressures investment yields, prompting insurers to seek capital-market solutions such as insurance-linked securities. Additionally, tightening Solvency II capital requirements and growing demand for cyber- and green-tech risk coverage are reshaping product mix and pricing dynamics.
For a deeper, data-rich assessment of Munich Re’s valuation and risk profile, consider exploring the company’s analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 6.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.16 > 1.0 |
| NWC/Revenue: -2.46% < 20% (prev 97.70%; Δ -100.2% < -1%) |
| CFO/TA 0.02 > 3% & CFO 6.26b > Net Income 6.16b |
| Net Debt (1.98b) to EBITDA (9.73b): 0.20 < 3 |
| Current Ratio: 0.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (129.4m) vs 12m ago -2.33% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 14.56% > 50% (prev 15.17%; Δ -0.62% > 0%) |
| Interest Coverage Ratio: 26.71 > 6 (EBITDA TTM 9.73b / Interest Expense TTM 351.0m) |
Altman Z'' 0.58
| A: -0.00 (Total Current Assets 6.12b - Total Current Liabilities 7.12b) / Total Assets 279.13b |
| B: 0.08 (Retained Earnings 21.01b / Total Assets 279.13b) |
| C: 0.03 (EBIT TTM 9.38b / Avg Total Assets 279.57b) |
| D: 0.13 (Book Value of Equity 32.24b / Total Liabilities 246.71b) |
| Altman-Z'' Score: 0.58 = B |
Beneish M -2.81
| DSRI: 1.18 (Receivables 5.91b/5.22b, Revenue 40.70b/42.49b) |
| GMI: 0.98 (GM 100.0% / 98.15%) |
| AQI: 1.20 (AQ_t 0.98 / AQ_t-1 0.82) |
| SGI: 0.96 (Revenue 40.70b / 42.49b) |
| TATA: -0.00 (NI 6.16b - CFO 6.26b) / TA 279.13b) |
| Beneish M-Score: -2.81 (Cap -4..+1) = A |
What is the price of MUV2 shares?
Over the past week, the price has changed by +3.83%, over one month by +0.04%, over three months by -1.26% and over the past year by +5.40%.
Is MUV2 a buy, sell or hold?
What are the forecasts/targets for the MUV2 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 585.3 | 10% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 649.1 | 22% |
MUV2 Fundamental Data Overview February 03, 2026
P/E Trailing = 10.7152
P/E Forward = 10.1112
P/S = 1.0843
P/B = 2.0518
P/EG = 0.3785
Revenue TTM = 40.70b EUR
EBIT TTM = 9.38b EUR
EBITDA TTM = 9.73b EUR
Long Term Debt = 7.40b EUR (from longTermDebt, last quarter)
Short Term Debt = 213.0m EUR (from shortTermDebt, last fiscal year)
Debt = 7.40b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.98b EUR (from netDebt column, last quarter)
Enterprise Value = 69.31b EUR (67.33b + Debt 7.40b - CCE 5.43b)
Interest Coverage Ratio = 26.71 (Ebit TTM 9.38b / Interest Expense TTM 351.0m)
EV/FCF = 24.52x (Enterprise Value 69.31b / FCF TTM 2.83b)
FCF Yield = 4.08% (FCF TTM 2.83b / Enterprise Value 69.31b)
FCF Margin = 6.95% (FCF TTM 2.83b / Revenue TTM 40.70b)
Net Margin = 15.14% (Net Income TTM 6.16b / Revenue TTM 40.70b)
Gross Margin = unknown ((Revenue TTM 40.70b - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 0.25 (Enterprise Value 69.31b / Total Assets 279.13b)
Interest Expense / Debt = 0.81% (Interest Expense 60.0m / Debt 7.40b)
Taxrate = 32.90% (979.0m / 2.98b)
NOPAT = 6.29b (EBIT 9.38b * (1 - 32.90%))
Current Ratio = 0.86 (Total Current Assets 6.12b / Total Current Liabilities 7.12b)
Debt / Equity = 0.23 (Debt 7.40b / totalStockholderEquity, last quarter 32.24b)
Debt / EBITDA = 0.20 (Net Debt 1.98b / EBITDA 9.73b)
Debt / FCF = 0.70 (Net Debt 1.98b / FCF TTM 2.83b)
Total Stockholder Equity = 32.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.20% (Net Income 6.16b / Total Assets 279.13b)
RoE = 19.17% (Net Income TTM 6.16b / Total Stockholder Equity 32.15b)
RoCE = 23.70% (EBIT 9.38b / Capital Employed (Equity 32.15b + L.T.Debt 7.40b))
RoIC = 16.26% (NOPAT 6.29b / Invested Capital 38.69b)
WACC = 5.14% (E(67.33b)/V(74.74b) * Re(5.65%) + D(7.40b)/V(74.74b) * Rd(0.81%) * (1-Tc(0.33)))
Discount Rate = 5.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.95%
[DCF Debug] Terminal Value 84.15% ; FCFF base≈2.65b ; Y1≈2.19b ; Y5≈1.57b
Fair Price DCF = 355.5 (EV 48.05b - Net Debt 1.98b = Equity 46.08b / Shares 129.6m; r=5.90% [WACC]; 5y FCF grow -21.22% → 2.90% )
EPS Correlation: -5.69 | EPS CAGR: -38.45% | SUE: -4.0 | # QB: 0
Revenue Correlation: -20.32 | Revenue CAGR: -2.49% | SUE: -0.20 | # QB: 0
EPS next Quarter (2026-03-31): EPS=12.31 | Chg30d=-0.181 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=50.92 | Chg30d=-0.149 | Revisions Net=-5 | Growth EPS=+6.0% | Growth Revenue=+3.6%